FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

BIOCON

424.9
+2.85 (0.68%)
Updated 03:29 23/09 IST

BIOCON Buy or Sell - FrontPage Forums

8 Users have submitted 13 trade ideas of Rs. 935,295 for BIOCON
Disclaimer
62% Bullish
38% Bearish

BIOCON Buy or Sell - Brokerage Reports

No. of reports in last year
8
No. of analysts
5
Average Consensus Forecast
303.75
Consensus Potential
-44.31%
See BIOCON Share Price Targets >>

BIOCON Ratings

Long term BIOCON rating by FrontPage users
4.4/5 (7 Ratings)
Find answers to all your questions on live BIOCON message board: Is BIOCON buy or sell? Should I buy BIOCON shares? Why are BIOCON shares falling? Should I invest in BIOCON stock?

  1. Home
  2. BIOCON Forum

BIOCON Share Price Discussion

P
Reputation: -800 • Yesterday 8:44 AM

Type
Buy
Instrument
BIOCON
Entry Price
₹423.6
Price@Trade
₹423.6
Target Price
₹460
Stop Price
₹390
Valid Till
Oct 23, 2020 3:20 AM
Margin
₹84,720 approx for 200 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
PVR
Entry Price
₹1,119
Price@Trade
₹1,115.5
Target Price
₹1,129
Stop Price
₹1,115
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹111,900 approx for 100 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21200 CE
Entry Price
₹172.15
Price@Trade
₹172.15
Target Price
₹300
Stop Price
₹150
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹172,150 approx for 1000 Qty
Status
Active
Like
Reply
R
Reputation: -38,239 • Yesterday 8:43 AM

Type
Buy
Instrument
NIFTY 24SEP20 11100 CE
Entry Price
₹79.75
Price@Trade
₹79.75
Target Price
₹100
Stop Price
₹65
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹538,312.5 approx for 6750 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21000 CE
Entry Price
₹310  ₹301.65
Price@Trade
₹310.95
Target Price
₹330
Stop Price
₹290
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹150,825 approx for 500 Qty
Status
Waiting for entry
Like
Reply (2)
See all replies
Trader Press @traderpress
Yesterday 8:43 AM

Update
Entry Price Modified
Price @ Update
₹306.25
Original Entry Price
₹310
New Entry Price
312.0
Trader Press @traderpress
Yesterday 8:43 AM

Update
Entry Price Modified
Price @ Update
₹301.65
Original Entry Price
₹312
New Entry Price
₹301.65
D
Reputation: -6,855 • Yesterday 8:43 AM

Type
Buy
Instrument
PAPERPROD
Entry Price
₹260  ₹286.75
Price@Trade
₹287.05
Target Price
₹300
Stop Price
₹250
Valid Till
Oct 23, 2020 3:20 AM
Margin
₹28,675 approx for 100 Qty
Status
Waiting for entry
Like
Reply (1)
See all replies
Dinesh @davdineshm
Yesterday 8:43 AM

Update
Entry Price Modified
Price @ Update
₹286.75
Original Entry Price
₹260
New Entry Price
₹286.75

Type
Buy
Instrument
RENUKA
Entry Price
₹9.1  ₹9.15
Price@Trade
₹9.15
Target Price
₹16
Stop Price
₹5
Valid Till
Sep 23, 2021 3:20 AM
Margin
₹233,828.25 approx for 25555 Qty
Status
Waiting for entry
Like
Reply (1)
See all replies
Self Traders @anilsakhiya
Yesterday 8:43 AM

Update
Entry Price Modified
Price @ Update
₹9.15
Original Entry Price
₹9.1
New Entry Price
₹9.15
S
Reputation: 5,565 • Yesterday 8:42 AM

Type
Buy
Instrument
NIFTY 24SEP20 11200 PE
Entry Price
₹67.15
Price@Trade
₹67.15
Target Price
₹300
Stop Price
₹0
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹20,145 approx for 300 Qty
Status
Active
Like
Reply
D
Reputation: -6,855 • Yesterday 8:41 AM

Type
Buy
Instrument
CYBERTECH
Entry Price
₹58  ₹66.05
Price@Trade
₹66.05
Target Price
₹70
Stop Price
₹55
Valid Till
Oct 23, 2020 3:20 AM
Margin
₹6,605 approx for 100 Qty
Status
Active
Like
Reply (2)
See all replies
Dinesh @davdineshm
Yesterday 8:42 AM

Update
Entry Price Modified
Price @ Update
₹66.05
Original Entry Price
₹58
New Entry Price
₹66.05
TrackerBot @trackerbot
Yesterday 8:42 AM

Update
Trade Entered
Entry Price
₹66.05

Type
Sell
Instrument
SILVERM 30NOV20 FUT
Entry Price
₹59,000
Price@Trade
₹59,016
Target Price
₹55,000
Stop Price
₹60,000
Valid Till
Sep 23, 2020 11:20 AM
Margin
₹287,300.63 approx for 25 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 8:42 AM

Update
Trade Entered
Entry Price
₹59,000

Type
Buy
Instrument
UBL
Entry Price
₹963
Price@Trade
₹963.45
Target Price
₹1,026
Stop Price
₹900
Valid Till
Sep 30, 2020 3:20 AM
Margin
₹770,400 approx for 800 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 8:42 AM

Update
Trade Entered
Entry Price
₹963
M
Reputation: -26,540 • Yesterday 8:41 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 21200 CE
Entry Price
₹178.55
Price@Trade
₹178.55
Target Price
₹500
Stop Price
₹0
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹4,463.75 approx for 25 Qty
Status
Active
Like
Reply
P
Reputation: -800 • Yesterday 8:41 AM

Type
Sell
Instrument
SRTRANSFIN
Entry Price
₹615.5
Price@Trade
₹615.5
Target Price
₹540
Stop Price
₹690
Valid Till
Sep 23, 2021 3:20 AM
Margin
₹123,100 approx for 200 Qty
Status
Active
Like
Reply
P
Reputation: 10,889 • Yesterday 8:41 AM

Mphasis is currently trading at Rs. 1390.35, up by 18.00 points or 1.31% from its previous closing of Rs. 1372.35 on the BSE.

The scrip opened at Rs. 1386.90 and has touched a high and low of Rs. 1418.00 and Rs. 1375.40 respectively. So far 10013 shares were traded on the counte...
Read more...
Like
Reply
N
Reputation: -14,266 • Yesterday 8:40 AM

Type
Buy
Instrument
BHARTIARTL
Entry Price
₹434.2
Price@Trade
₹434.2
Target Price
₹480
Stop Price
₹400
Valid Till
Sep 23, 2021 3:20 AM
Margin
₹434,200 approx for 1000 Qty
Status
Active
Like
Reply
D
Reputation: -6,855 • Yesterday 8:40 AM

Type
Buy
Instrument
CDSL
Entry Price
₹440  ₹480
Price@Trade
₹479.25
Target Price
₹500
Stop Price
₹435
Valid Till
Oct 23, 2020 3:20 AM
Margin
₹48,000 approx for 100 Qty
Status
Active
Like
Reply (2)
See all replies
Dinesh @davdineshm
Yesterday 8:41 AM

Update
Entry Price Modified
Price @ Update
₹480
Original Entry Price
₹440
New Entry Price
₹480
TrackerBot @trackerbot
Yesterday 8:41 AM

Update
Trade Entered
Entry Price
₹480
S
Reputation: -13,857 • Yesterday 8:40 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 21400 PE
Entry Price
₹208  ₹214.3
Price@Trade
₹220
Target Price
₹400
Stop Price
₹160
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹428,600 approx for 2000 Qty
Status
Exited
Exit Price
₹217.05
Net P&L
+₹5,500 (+1.28%)
Like
Reply (4)
See all replies
SSS @sss-BJeY5QpOV
Yesterday 8:41 AM

Update
Entry Price Modified
Price @ Update
₹214.3
Original Entry Price
₹218
New Entry Price
₹214.3
TrackerBot @trackerbot
Yesterday 8:42 AM

Update
Trade Entered
Entry Price
₹214.3
SSS @sss-BJeY5QpOV
Yesterday 8:43 AM

Update
Exited
Exit Price
₹217.05
Net P&L
+₹5,500 (+1.28%)

Type
Buy
Instrument
BANKNIFTY 24SEP20 21000 CE
Entry Price
₹305.75
Price@Trade
₹321.1
Target Price
₹425
Stop Price
₹250
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹7,643,750 approx for 25000 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
SwingTraders Academy @rameswaran
Yesterday 8:41 AM

Update
Exited before entry
Price @ Update
₹308.85

Type
Sell
Instrument
BANKNIFTY 24SEP20 21200 CE
Entry Price
₹181.7
Price@Trade
₹181.7
Target Price
₹0
Stop Price
₹280
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹733,915.6 approx for 175 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
NIFTY 24SEP20 11100 CE
Entry Price
₹79.1
Price@Trade
₹79.1
Target Price
₹150
Stop Price
₹50
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹5,932.5 approx for 75 Qty
Status
Active
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • BIOCON - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization36,660
    Enterprise Value36,305
    Price to Earnings149.8
    Price to Book Value5.15
    Return on Capital Employed0.04
    Return on Equity0.04
    Face Value5
    Dividend YieldNA
  • BIOCON - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    18-May-20Nirmal BangSell272
    18-May-20Axis DirectBuy474
    27-Jan-20ICICIdirect.comHold310
    27-Jan-20Nirmal BangSell252
    27-Jan-20Motilal OswalNeutral300
    BIOCON Brokerage Price Target
  • BIOCON Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 23424.6429418.2423.9
    Sep 21453.95453.95425.35429.35
    Sep 18442.75463.9442.75454
    Sep 17439444.85432.55442.2
    Sep 16440.05453.9434.55438.65
  • BIOCON Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹420.1
    30 Day Moving Average₹411.66
    50 Day Moving Average₹413.23
    100 Day Moving Average₹393.9
    200 Day Moving Average₹346.39
  • BIOCON - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,4252,587.9-0.06
    Operating Profit318591.8-0.46
    Profit Before Tax305536.2-0.43
    Net Income238519.3-0.54
  • BIOCON - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds7,1156,7370.06
    Total Liabilities1,1251,0450.08
    Total Assets8,2407,7830.06
  • BIOCON - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity355185.80.91
    Cash from Investing Activity-553104-6.32
    Cash from Financing Activity-54-238.3-0.77
    Net Cash Flow-25251.5-5.89
  • BIOCON - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.07
    Return on Equity0.040.08
    Return on Capital Employed0.040.08
  • BIOCON - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.08
    3 Year CAGR Growth in Operating Profit-0.22
    3 Year CAGR Growth in EBIDTA-0.21
    3 Year CAGR Growth in Net Income-0.34
    3 Yr CAGR Growth - Diluted EPS-0.78
  • BIOCON - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.25
    5 Year CAGR Growth in Operating Profit-0.18
    5 Year CAGR Growth in EBIDTANA
    5 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.71
  • BIOCON - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 5:26 AM
    Biocon appoints Anupam Jindal as new CFO
    The Economic Times
    NewsBot
    Sep 21 7:46 AM
    Stock market update: BSE MidCap index sheds nearly 3%; Jindal Steel & Power dips 8%
    The Economic Times
    NewsBot
    Sep 9 7:56 AM
    Stock market update: Nifty Pharma index gains 1%; Biocon rises 3%
    The Economic Times
    NewsBot
    Sep 7 4:06 AM
    C-CAMP launches fourth edition of bio-entrepreneurship competition
    The Economic Times
    NewsBot
    Sep 7 4:01 AM
    C-CAMP launches fourth edition of bio-entrepreneurship competition
    The Economic Times
    NewsBot
    Sep 3 6:41 AM
    LIVE Market Technicals with CK Narayan
    The Economic Times
    NewsBot
    Sep 2 5:36 AM
    Stock market update: Pharma stocks down; Sun Pharma loses nearly 2%
    The Economic Times
    NewsBot
    Sep 1 3:06 AM
    Using science is reliable way forward in managing Covid-19: Kiran Mazumdar-Shaw
    The Economic Times
    NewsBot
    Sep 1 4:58 AM
    Biocon shares jump 5% on launch of diabetes drug in US
    Moneycontrol
    NewsBot
    Sep 1 3:51 AM
    Glargine launch in US opens up a huge opportunity for Biocon: Kiran Mazumdar Shaw
    The Economic Times
  • BIOCON - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • BIOCON - More Information

    keyboard_arrow_down

    Biocon Ltd:
    Biocon Limited is a biopharmaceutical firm in India, engaged in developing, manufacturing and selling pharmaceutical products for oncology, diabetes and autoimmune diseases in the nation as well as abroad. The company has several sectors of operations such as small molecules, branded formulations, research services and more.
    The company is manufacturing insulin lispro, insulin glargine, insulin aspart, recombinant human insulin, monoclonal antibodies, small molecules viz. generic formulations and active pharmaceutical ingredients and more, along with botanical products. Besides that, the company has branded formulation products under brands such as Insugen, BIOMAb, ALZUMAb, EGFR, Basalog and CANMAb. Biocon Limited has certifications such as ISO 9001, ISO 14001:2004, ISO 9001:2000, ISO 15189:2003 and OHSAS 18001:1999. The company has been developing its entire research system based upon small and large molecules, oligonucleotides and antibody-drug conjugates. Clinigene International Ltd and Syngene International Ltd are the two subsidiaries of Biocon Limited. The company has a global intervention in approximately 120 countries.
    About Company Information:
    Biocon Limited was incepted in 1978 and is headquartered in Bangalore, India. Biocon Limited was found when an Indian entrepreneur signed a joint venture with Ireland based firm Biocon Biochemicals Limited in 1978. The company started manufacturing and exporting enzymes to USA and Europe from 1979. Biocon Biochemicals Limited was acquired by Unilever plc and merged with Unilever’s subsidiary Quest International.
    In 1990, the company enhanced its in-house research programme by introducing new technologies. In 1993, the R&D, along with manufacturing facilities of the company, was certified ISO 9001 by RWTUV, Germany. Syngene International Pvt. Ltd was incorporated by the company in 1994 as a Custom Research Company for addressing the exponentially increasing need for outsourced Research & Development in the pharmaceutical sector.
    Developing an efficient manufacturing facility, Biocon Limited started to venture its initiatives for human healthcare in the medicine market and business since 1997. In 1998, Unilever had gone for a deal with ICI for selling its speciality chemicals division, which includes Quest International.
    A totally automated submerged fermentation plant, for the first time in its history of operation, was commissioned by the company in 2000, for manufacturing speciality pharmaceuticals. Clinigene, India’s first Clinical Research Organisation for providing clinical research and development was commissioned by the company in 2000. US FSA approved Biocon Limited as India’s first pharmaceutical company to manufacture the cholesterol-lowering molecule lovastatin.
    In 2005, a commercial agreement was signed by Biocon Limited for supplying insulin API to Asia, Africa and the Middle East. Nation’s largest biotechnology hub, having an integrated set up of manufacturing facilities and research laboratories with a spreading of 90 acres in Karnataka Industrial Areas Development Board—namely, Biocon Park was established by the company in 2006. Country’s largest multi-product Biologics facility was also established at Biocon Park.
    An MoU was signed between Biocon and Neopharma, resulting as a joint venture firm Neobiocon in July 2007. A strategic partnership was established between the company and IATRICa, Inc for developing jointly a range of immunoconjugates regarding the immunotherapy of cancers and infectious diseases in January 2008.
    BASALOG, long-lasting basal insulin for Type 1 & Type 2 Diabetics were introduced by Biocon Limited in 2009. Biocon Cell was launched as the resultant of the partnership between Biocon Limited and ISB for Innovation Management in the same year. AxiCorp GmbH, the German subsidiary of Biocon had been sold by the company in 2011, to its existing promoters and shareholders. ALZUMAb, was launched by Biocon Limited in 2013 for the psoriasis patients in India.
    In 2014, CANMAb – Trastuzumab, a medicine for the treatment of breast cancer was launched by the company in India. A world-class premium devices facility was inaugurated by Biocon at Bangalore in 2015 along with the introduction of Basalog One in India. Mylan and Biocon jointly submitted a proposal for Biosimilar Trastuzumab to USFDA in 2016.
    Biocon Limited declared that along with Mylan it is going to enhance the introduction of adalimumab biosimilar in Europe, as Mylan has an in-licensing arrangement with Fujifilm Kyowa Kirin Biologics.
    How Biocon Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Biocon Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Biocon Ltd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Advik Laboratories Ltd. ADVLAB
    Ahlcon Parenterals (India) Ltd. AHLPAR
    Ajanta Pharma Ltd. AJAPHL
    Aurobindo Pharma Ltd. AUROBP
    Bharat Immunological & Biologicals Corporation Ltd. BHAIMM
    Biofil Chemicals & Pharmaceuticals Ltd. BIOCHE
    Biowin Pharma (India) Ltd. BIOPHA
    Bliss GVS Pharma Ltd. BLIGVS
    Brabourne Enterprises Ltd.[Amalgamated] RPGLIF
    Brawn Biotech Ltd. BRAPHA
    Brooks Laboratories Ltd. BROLAB
    Cadila Healthcare Ltd. CADHEA
    Caplin Point Laboratories Ltd. CAPPOI
    Cipla Ltd. CIPLTD
    Claris Lifesciences Ltd. CORELA
    Colinz Laboratories Ltd. COLILA
    Combat Drugs Ltd. COMDRU
    Concord Drugs Ltd. CONDRU
    Coral Laboratories Ltd. CORLAB
    Desh Rakshak Aushdhalaya Ltd. DESRAK
    DIL Ltd. DILLIM
    Divi's Laboratories Ltd. DIVIL
    Dolphin Laboratories Ltd. DOLLAB
    Dr. Datsons Labs Ltd. AANLIF
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Ganga Pharmaceuticals Ltd. GANPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Ipca Laboratories Ltd. IPCLAB
    Ishita Drugs & Industries Ltd. ISHDRU
    J B Chemicals & Pharmaceuticals Ltd. JBCH
    Jagsonpal Pharmaceuticals Ltd. JAGPHA
    Jenburkt Pharmaceuticals Ltd. JENPHA
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Kabra Drugs Ltd. KABDRU
    Kamron Laboratories Ltd. KAMLAB
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Mangalam Drugs and Organics Ltd. MANDRU
    New Heaven Chemicals and Industries Ltd. TRAMED
    NGL Fine - Chem Ltd. NGLFIN
    Norris Medicines Ltd. NORMED
    Novartis India Ltd. NOVAIN
    Nutraplus India Ltd. NUTPRO
    Omega Labora.Ltd. OMELAB
    Oriental Remedies & Herbals Ltd. ORIREM
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Procter & Gamble Health Ltd. MERCLT
    Ranbaxy Laboratories Ltd. RANLAB
    RPG Life Sciences Ltd. RPGLI
    Rubra Medicaments Ltd. RUBMED
    Sanofi India Ltd. AVEPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Trans Asia Corporation Ltd. TRAASI
    Wockhardt Ltd. WOCLTD
    Wyeth Ltd. WYELTD
    Yogi Healthcare Ltd. COREHE
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020